Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Are Drugs Bad, The Future Cannabinoids as a Medicine 3.0 ft. Dr. Matthew Moore

Are Drugs Bad, The Future Cannabinoids as a Medicine 3.0 ft. Dr. Matthew Moore

FromThe Dime


Are Drugs Bad, The Future Cannabinoids as a Medicine 3.0 ft. Dr. Matthew Moore

FromThe Dime

ratings:
Length:
49 minutes
Released:
Nov 16, 2023
Format:
Podcast episode

Description

As rumors of rescheduling grow more prominent, concerns about big pharma's potential control over the industry are escalating. We invited Dr. Matt Moore back for a third time to shed light on the challenges and opportunities in the development and research of cannabinoid and psychedelic drugs. For those unfamiliar with Dr. Moore, he is an accomplished scientist with extensive experience in the pharmaceutical, cannabis, and psychedelic industries, adept at managing projects from pre-clinical stages to post-approval."This week, we sit down with Dr. Matthew Moore to discuss.Does Big Pharma benefit from a rescheduling of Cannabis?Cannabinoid Clinical Trials, challenges, and opportunities Brian Johnson and Medicine 3.0#ReschuedlingCannabis #clinicaltrials #personalizedmedicineFollow us: Our Links.At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry.8th Revolution Cannabinoid Playbook is an Industry-leading report covering the entire cannabis supply chain The Dime is a top 5% most shared  global podcast The Dime is a top 50 Cannabis Podcast Sign up for our playbook here:? YouTube:  The Dime? Instagram:  The Dime? Twitter: Bryan Fields, Kellan Finney
Released:
Nov 16, 2023
Format:
Podcast episode

Titles in the series (100)

Welcome to The Dime Podcast - your ultimate guide to the cannabis industry. Join us every Thursday as we interview top industry leaders to share valuable insights, tips, and frameworks for success. Whether you're an entrepreneur, investor, or just interested in the industry, we've got something for you. Tune in for a simplified approach to complex challenges and something new in each episode.